ArticleFrontiers in pharmacology2020
Long-Term Toxicity Study of Topical Administration of a Highly-Stable rh-aFGF Carbomer 940 Hydrogel in a Rabbit Skin Wound Model.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Advanced hydrogel-based drug delivery systems for psoriasis management: From material design to multi-target therapies.International journal of pharmaceutics: X · 2026Review
- Metronidazole-Loaded Cyclodextrin Nanogels for Antibacterial Therapy and Microbiota Regulation in Periodontitis.Advanced healthcare materials · 2026Article
- Chinese Expert Consensus for the Application of rh-aFGF for Chronic Refractory Wounds.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Definition of critical skin defect and concepts of structural and functional repairs: Proposal and verification in a rat model.Animal models and experimental medicine · 2026Article
- Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.Current drug metabolism · 2025Review
- Comprehensive Biosafety Profile of Carbomer-Based Hydrogel Formulations Incorporating Phosphorus Derivatives.Gels (Basel, Switzerland) · 2024Article
- Highly Absorbent Egg White/Carbomer-940 Hydrofilm as a Potential Diabetic Wound Dressing.Macromolecular bioscience · 2024Article
- Hydrophobic Drug Carrier from Polycaprolactone-Polymers · 2023Article
- Framework for defining pesticide maximum residue levels in feed: applications to cattle and sheep.Pest management science · 2023Article
- Ionic complexation improves wound healing in deep second-degree burns and reduces in-vitro ciprofloxacin cytotoxicity in fibroblasts.Scientific reports · 2022Article
- [Research advances on the role of acid fibroblast growth factor in promotion of wound healing].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Article
- Log P Determines Licorice Flavonoids Release Behaviors and Classification from CARBOMER Cross-Linked Hydrogel.Pharmaceutics · 2022Article
- Hypoglycemic Efficacy of Rh-aFGF Variants in Treatment of Diabetes in ZDF Rats.Frontiers in cell and developmental biology · 2021Article
- Topical recombinant human acidic fibroblast growth factor: An effective therapeutic agent for facemask wearing-induced pressure sores.Dermatologic therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed a highly stable recombinant human acidic fibroblast growth factor (rh-aFGF) carbomer 940 hydrogel for wound healing. This study aimed to reveal toxicity target organs and the toxicity dose-response in the long-term administration of rh-aFGF carbomer 940 hydrogel in a rabbit skin wound model. New Zealand rabbits were topically administrated rh-aFGF carbomer 940 hydrogel at a daily dose of 900 IU/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.